NeRRe Therapeutics raises £20 million in a Series B2 financing round
- New funds to evaluate orvepitant as a treatment for the disabling chronic cough
associated with idiopathic pulmonary fibrosis (IPF). - New investor Columbus Venture Partners joins existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners, OrbiMed, and the UK Government’s Future Fund.